Nanox.AI tunes medical imaging AI for Intel Core Ultra chips

Nanox.AI Ltd., a subsidiary of Nano-X Imaging Ltd. (NASDAQ: NNOX), announced the optimization of its medical imaging AI application framework for Intel Core Ultra processors using Intel's OpenVINO toolkit.

The framework is designed to support AI applications running on an on-premise edge device within healthcare facilities, allowing organizations to deploy CT imaging AI applications while keeping imaging data within their own infrastructure.

According to the company, the optimized framework ran inference on Intel Core Ultra-class hardware using OpenVINO. Intel Core Ultra processors include CPU, GPU, and NPU compute resources, while OpenVINO is a toolkit used to optimize and deploy AI workloads across Intel hardware.

Nanox.AI's solutions analyze routine CT scans to identify findings associated with chronic conditions in areas including cardiac, liver, and bone health.

"Nanox.AI is focused on helping healthcare organizations deploy advanced medical imaging AI applications efficiently within their existing infrastructure," said Sharon Saban, General Manager of Nanox.AI. "Our work with Intel demonstrates how optimized edge inference can help bring AI-enabled imaging insights closer to the point of care."

"Healthcare organizations need practical ways to bring AI closer to clinical workflows while supporting performance, responsiveness and local data control," said Alex Flores, General Manager, Health and Life Science, Edge Computing Group, Intel. "Nanox.AI's optimization work with Intel Core Ultra processors and Intel's OpenVINO toolkit shows how edge AI can help medical imaging applications run efficiently on-premise."

Nanox.AI's technology has been included in Intel's published partner resources as an example of a solution built with Intel technology.

You May Also Be Interested In

• ADARx Pharmaceuticals files for proposed IPO
• Lion Copper and Gold Corp. to rename and consolidate shares for Nasdaq bid
• SOS Limited receives NYSE non-compliance notice over share price